(IRON) Disc Medicine - Ratings and Ratios
Red, Blood, Iron, Drug, Clinical
Description: IRON Disc Medicine
Disc Medicine Inc. (NASDAQ:IRON) is a biotechnology company listed on the NASDAQ stock exchange, categorized under the biotechnology sub-industry. As a common stock, IRON represents ownership in the company.
The companys market capitalization stands at approximately $2.045 billion USD, indicating its size and investor recognition. Notably, the stock has a beta of 2.496, suggesting that its price movements are more volatile than the overall market, which could be attributed to the inherent risks associated with the biotechnology sector.
With a return on equity (RoE) of -22.61%, Disc Medicine is currently operating at a loss, which is not uncommon for companies in the biotechnology industry that are often in the development phase and not yet profitable. The absence of a price-to-earnings (P/E) ratio further indicates that the company is not generating positive earnings.
Key economic drivers for Disc Medicine include the success of its pipeline products, particularly those in clinical development, and the overall demand for its potential therapies. Key performance indicators (KPIs) to watch include clinical trial progress, regulatory approvals, and eventual commercialization of its products. The companys ability to manage its cash burn rate and secure funding will also be crucial in determining its financial health and ability to achieve its development goals.
Investors should closely monitor updates on the companys clinical trials, partnerships, and financial management as these factors will significantly influence the stocks performance. The biotechnology sector is known for its high-risk, high-reward nature, and Disc Medicines stock is likely to be sensitive to news and developments related to its pipeline and financials.
IRON Stock Overview
| Market Cap in USD | 2,141m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-08-12 |
IRON Stock Ratings
| Growth Rating | 13.2% |
| Fundamental | 16.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 6.59% |
| Analyst Rating | 4.73 of 5 |
IRON Dividends
Currently no dividends paidIRON Growth Ratios
| Growth Correlation 3m | 77.5% |
| Growth Correlation 12m | 5.2% |
| Growth Correlation 5y | -45.2% |
| CAGR 5y | 11.13% |
| CAGR/Max DD 3y | 0.16 |
| CAGR/Mean DD 3y | 0.42 |
| Sharpe Ratio 12m | 0.26 |
| Alpha | 0.22 |
| Beta | 0.335 |
| Volatility | 53.45% |
| Current Volume | 290.1k |
| Average Volume 20d | 255k |
| Stop Loss | 58 (-3.9%) |
| Signal | -0.26 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-145.4m TTM) > 0 and > 6% of Revenue (6% = -8.72m TTM) |
| FCFTA -0.14 (>2.0%) and ΔFCFTA 0.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.20 (>3.0%) and CFO -134.2m > Net Income -145.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 32.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (35.0m) change vs 12m ago 36.55% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover -24.73% (prev 0.0%; Δ -24.73pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -56.10 (EBITDA TTM -133.3m / Interest Expense TTM 2.38m) >= 6 (WARN >= 3) |
Altman Z'' -5.09
| (A) 0.96 = (Total Current Assets 661.6m - Total Current Liabilities 20.6m) / Total Assets 665.1m |
| (B) -0.58 = Retained Earnings (Balance) -387.3m / Total Assets 665.1m |
| (C) -0.23 = EBIT TTM -133.5m / Avg Total Assets 587.6m |
| (D) -7.60 = Book Value of Equity -387.1m / Total Liabilities 50.9m |
| Total Rating: -5.09 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 16.73
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -6.21% = -3.11 |
| 3. FCF Margin -64.97% = -7.50 |
| 4. Debt/Equity 0.05 = 2.50 |
| 5. Debt/Ebitda -0.22 = -2.50 |
| 6. ROIC - WACC (= -30.69)% = -12.50 |
| 7. RoE -26.60% = -2.50 |
| 8. Revenue Trend data missing |
| 9. EPS Trend -53.31% = -2.67 |
What is the price of IRON shares?
Over the past week, the price has changed by +0.00%, over one month by +2.55%, over three months by +15.99% and over the past year by +26.55%.
Is Disc Medicine a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IRON is around 57.13 USD . This means that IRON is currently overvalued and has a potential downside of -5.32%.
Is IRON a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IRON price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 99.7 | 65.3% |
| Analysts Target Price | 99.7 | 65.3% |
| ValueRay Target Price | 62.9 | 4.3% |
Last update: 2025-09-05 04:48
IRON Fundamental Data Overview
CCE Cash And Equivalents = 650.0m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -145.4m + Cost of Revenue 40.0k = -145.3m USD
P/B = 3.492
Beta = 2.502
Revenue TTM = -145.3m USD
EBIT TTM = -133.5m USD
EBITDA TTM = -133.3m USD
Long Term Debt = 28.7m USD (from longTermDebt, last quarter)
Short Term Debt = 632.0k USD (from shortTermDebt, last quarter)
Debt = 29.4m USD (Calculated: Short Term 632.0k + Long Term 28.7m)
Net Debt = -96.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.52b USD (2.14b + Debt 29.4m - CCE 650.0m)
Interest Coverage Ratio = -56.10 (Ebit TTM -133.5m / Interest Expense TTM 2.38m)
FCF Yield = -6.21% (FCF TTM -94.4m / Enterprise Value 1.52b)
FCF Margin = -64.97% (FCF TTM -94.4m / Revenue TTM -145.3m)
Net Margin = -100.0% (Net Income TTM -145.4m / Revenue TTM -145.3m)
Gross Margin = -100.0% ((Revenue TTM -145.3m - Cost of Revenue TTM 40.0k) / Revenue TTM)
Tobins Q-Ratio = -3.93 (set to none) (Enterprise Value 1.52b / Book Value Of Equity -387.1m)
Interest Expense / Debt = 3.10% (Interest Expense 910.0k / Debt 29.4m)
Taxrate = 21.0% (US default)
NOPAT = -133.5m (EBIT -133.5m, no tax applied on loss)
Current Ratio = 32.11 (Total Current Assets 661.6m / Total Current Liabilities 20.6m)
Debt / Equity = 0.05 (Debt 29.4m / last Quarter total Stockholder Equity 614.2m)
Debt / EBITDA = -0.22 (Net Debt -96.4m / EBITDA -133.3m)
Debt / FCF = -0.31 (Debt 29.4m / FCF TTM -94.4m)
Total Stockholder Equity = 546.5m (last 4 quarters mean)
RoA = -21.86% (Net Income -145.4m, Total Assets 665.1m )
RoE = -26.60% (Net Income TTM -145.4m / Total Stockholder Equity 546.5m)
RoCE = -23.20% (Ebit -133.5m / (Equity 546.5m + L.T.Debt 28.7m))
RoIC = -23.50% (NOPAT -133.5m / Invested Capital 567.9m)
WACC = 7.19% (E(2.14b)/V(2.17b) * Re(7.25%)) + (D(29.4m)/V(2.17b) * Rd(3.10%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 99.24 | Cagr: 20.94%
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -94.4m)
EPS Correlation: -53.31 | EPS CAGR: -63.51% | SUE: -3.88 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0%
Additional Sources for IRON Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle